Cardiovascular Event Reduction and Adverse Events Among Subjects Attaining Low-Density Lipoprotein Cholesterol <50 mg/dl With Rosuvastatin: The JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin)

Abstract
No abstract available
Funding Information
  • AstraZeneca LP
  • AstraZeneca
  • Novartis
  • Merck
  • Abbott
  • Roche
  • Sanofi-Aventis